Starch Medical Launches New, Bioinert Surgical Hemostats

Wednesday, December 3, 2008 General News
Email Print This Page Comment
Font : A-A+

SAN JOSE, Calif., Dec. 2 Starch Medical Inc, a San Jose,CA-based medical device manufacturer, announces the CE approval of itsPerClot(TM) Polysaccharide Hemostatic System (PHS) and the StarFoam(TM)Absorbable Polysaccharide Hemostat. Introduction of PerClot(TM) PHS willcommence this month in the European Union and other select internationalmarkets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launchduring the 2nd quarter, 2009.

PerClot(TM) PHS is an absorbable, surgical hemostat composed of AbsorbableModified Polymers (AMP(TM)). AMP(TM) technology incorporates sophisticated,plant-based polymer modification processes that yield biocompatible,polysaccharide particles. There is no thrombin, collagen, or other human oranimal components in AMP(TM) particles. A family of customized, single-useapplication instruments will enhance the delivery of AMP(TM) to the wound sitefor the control of capillary, venous and arterial bleeding in both open andminimally invasive surgical procedures.

The StarFoam(TM) Absorbable Polysaccharide Hemostat, also developed withAMP(TM) technology, is produced in a hemostatic foam (wafer) configuration.Application of StarFoam(TM) will feature a simple "press and release"technique.

David Lang, President of SMI, commented, "The clinical introduction ofPerClot(TM) PHS and its proprietary, integrated AMP(TM) technology representsthe next generation of polysaccharide hemostatic agents. The StarFoam(TM)product line will offer surgeons a choice of hemostatic formats for a range ofsurgical wounds. Compared to current polysaccharide based hemostats,PerClot(TM) PHS and StarFoam(TM) demonstrate superior hydrophilic action andenhanced adhesive strength. These performance features, coupled with customdelivery systems, have been favorably received in a diverse range of surgicalapplications in Europe, Asia and Latin America."

SMI is a privately-held medical device company engaged in the design,manufacture, marketing and licensing of breakthrough, hemostatic solutions.Starch Medical's proprietary, patent-pending technology platform (AMP(TM)),including powders, foams and films, will focus on the worldwide, multi-billiondollar biomaterial, hemostasis, and wound care marketplace. For additionalinformation, distribution inquiries, and licensing options, visithttp://www.starchmedical.com.

SOURCE Starch Medical Inc


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook